Given the disease-driving role of megakaryocytes in MPNs [18–23], these studies collectively suggest targeting YBX1 function may selectively antagonize megakaryocyte over erythroid development in MPN patients, and importantly, potentially spare healthy megakaryocyte development. This evidence concerns the gene YBX1 and myeloproliferative neoplasm.